T A B L E O F C O N T E N T S
to 1.67) , or the rate of exacerbations per patient year (rate ratio (RR) 0.96; 95% CI 0.89 to 1.02) between inhaled corticosteroids and long-acting beta 2 -agonists. The incidence of pneumonia, our co-primary outcome, was significantly higher among patients on inhaled corticosteroids than on long-acting beta 2 -agonists whether classified as an adverse event (OR 1.38; 95% CI 1.10 to 1.73) or serious adverse event (Peto OR 1.48; 95% CI 1.13 to 1.93) . Results of the secondary outcomes analysis were as follows. Mortality was higher in patients on inhaled corticosteroids compared to patients on long-acting beta 2 -agonists (Peto OR 1.17; 95% CI 0.97 to 1.42), although the difference was not statistically significant. Patients treated with beta 2 -agonists showed greater improvements in pre-bronchodilator FEV 1 compared to those treated with inhaled corticosteroids (mean difference (MD) 18.99 mL; 95% CI 0.52 to 37.46), whilst greater improvements in health-related quality of life were observed in patients receiving inhaled corticosteroids compared to those receiving long-acting beta 2 -agonists (St George's Respiratory Questionnaire (SGRQ) MD -0.74; 95% CI -1.42 to -0.06). In both cases the differences were statistically significant but rather small in magnitude. There were no statistically significant differences between ICS and LABA in the number of hospitalisations due to exacerbations, number of mild exacerbations, peak expiratory flow, dyspnoea, symptoms scores, use of rescue medication, adverse events, all cause hospitalisations, or withdrawals from studies.
Authors' conclusions
Placebo-controlled trials have established the benefits of both long-acting beta-agonist and inhaled corticosteroid therapy for COPD patients as individual therapies. This review, which included trials allowing comparisons between LABA and ICS, has shown that the two therapies confer similar benefits across the majority of outcomes, including the frequency of exacerbations and mortality. Use of long-acting beta-agonists appears to confer a small additional benefit in terms of improvements in lung function compared to inhaled corticosteroids. On the other hand, inhaled corticosteroid therapy shows a small advantage over long-acting beta-agonist therapy in terms of health-related quality of life, but inhaled corticosteroids also increase the risk of pneumonia. This review supports current guidelines advocating long-acting beta-agonists as frontline therapy for COPD, with regular inhaled corticosteroid therapy as an adjunct in patients experiencing frequent exacerbations.
P L A I N L A N G U A G E S U M M A R Y

Comparing inhaled corticosteroids with long-acting beta 2 -agonists in treating chronic obstructive pulmonary disease (COPD)
Inhalers containing corticosteroids, long-acting beta 2 -agonists or both can be used to treat severe chronic obstructive pulmonary disease (COPD). However, the benefits and harms of the two individual treatments are unclear when comparing one treatment with the other.
We looked at clinical trials that compared the two kinds of inhalers to find the effects of each on health and well-being in patients with COPD. We found seven studies (involving 5997 participants) comparing the long-term benefits and side effects of inhaled corticosteroids and long-acting beta 2 -agonists for treating COPD. Overall, we found no significant difference between the two drugs in the number of people having an exacerbation (worsening of COPD symptoms). More people taking inhaled corticosteroids suffered episodes of pneumonia compared to people using long-acting beta 2 -agonists, although pneumonia was extremely rare in both groups. Inhaled corticosteroids do not improve lung function as much as long-acting beta 2 -agonists but did improve patients' quality of life more than long-acting beta 2 -agonists. The differences in lung function and quality of life were rather small.
B A C K G R O U N D
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the treatment of patients with chronic obstructive pulmonary disease (COPD) state that beta 2 -agonists are a central therapy for the alleviation of symptoms (GOLD 2010) . Inhaled long-acting beta 2 -agonists (LABAs) improve lung function (Boyd 1997) and health-related quality of life (Jones 1997) and are recommended by current National Institute for Health and Clinical Excellence (NICE) guidelines in the treatment of COPD (NICE 2010 This evidence for the effectiveness of LABA and ICS for COPD has led to the development of combination therapies that contain both an inhaled corticosteroid and a long-acting beta 2 -agonist (Calverley 2003 a). However, the relative benefits of LABA and ICS in the treatment of COPD has not been fully explored. Recent findings from clinical trials suggest that the impact of combination therapies on a range of outcomes may not be a simple additive effect, for example in the comparisons of combination versus monocomponents (ICS or LABA) for exacerbation rates (Calverley 2003 a; . This makes an investigation of the relative added value of LABAs compared to ICS even more important. Of particular concern is the relative impact of the treatments on adverse outcomes such as mortality.
The aim of this review is to evaluate the relative added value of inhaled corticosteroids compared to long-acting beta 2 -agonists on clinical endpoints.
O B J E C T I V E S
To determine the relative effects of inhaled corticosteroids and long-acting beta 2 -agonists on clinical endpoints in patients with stable COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised trials (RCTs) that included comparisons between inhaled corticosteroids and long-acting beta 2 -agonists in the treatment of patients with stable COPD.
Types of participants
We included patients with a clinical diagnosis of COPD, and not asthma, that fulfilled any of the following internationally recognised diagnostic guidelines: American Thoracic Society (ATS), European Respiratory Society (ERS) and Global Initiative for Chronic Obstructive Lung Disease (GOLD). We only included studies with patients who were clinically stable at study entry, as defined by an exacerbation-free study run-in period, and that had excluded patients with significant comorbidity.
Types of interventions
We included regular inhaled corticosteroids compared with regular inhaled long-acting beta 2 -agonists administered by any inhalation device. We included the following inhaled corticosteroid versus inhaled long-acting beta 2 -agonist comparisons. 
Searching other resources
We checked the reference lists of all included randomised controlled trials and review articles for additional references. We contacted authors of identified randomised trials about other published and unpublished studies.
Data collection and analysis
Selection of studies
Two of us (SS and DJE) independently assessed the titles and abstracts of all retrieved trials. Using the full text of each study, we independently selected trials for inclusion in the review. We resolved disagreements about relevance by consensus.
Data extraction and management
Three of us (SS, DJE and CK) independently extracted data from the included studies and the data were then aggregated. We sought data missing from the publications through correspondence with the study authors. We extracted variance data from all arms of the included studies to enable calculation of the variance of the ICS versus LABA difference, where this was not reported. We combined data from all trials using RevMan 5.
Assessment of risk of bias in included studies
We assessed the risk of bias for all included studies according to recommendations outlined in the 
Measures of treatment effect
We summarised proportional outcomes, such as the proportion who improved, using an odds ratio (OR) with a fixed-effect Mantel-Haenszel model, unless zero cells were present in which case we used Peto odds ratios. We analysed continuous data as weighted mean difference (MD) with a fixed-effect model. In trials where individual group data were not reported and treatment effects were only given as differences between treatment groups, we analysed data using the generic inverse variance (GIV) function with a fixedeffect model. A number of trials reported the difference between ICS and LABA arms but did not report the appropriate variance around this difference. In this case, we calculated the variance of the difference between ICS and LABA using the variances of all the trial arms, see Appendix 1. We did not impute variances from other studies in any of the analyses in this review.
Dealing with missing data
We contacted investigators and manufacturers of the preparations for missing data, where necessary.
Assessment of heterogeneity
We performed tests for heterogeneity using the I 2 statistic in RevMan 5. Where I 2 was greater than 20% we also conducted a sensitivity analysis by pooling data with a random-effects model and comparing this to the results of the fixed-effect model.
Assessment of reporting biases
We planned to inspect funnel plots for signs of publication bias.
Subgroup analysis and investigation of heterogeneity
We pooled the analysis across studies but performed subgroup analyses for each corticosteroid versus beta 2 -agonist comparison. The treatment periods were stratified into less than one year, and more than one year. We pooled studies with different doses of the same inhaled corticosteroid and planned to carry out subgroup testing to compare different doses, when the data allowed this.
Sensitivity analysis
We planned to carry out sensitivity analysis based on study quality.
R E S U L T S Description of studies
Results of the search
The electronic search returned 431 references. From these, we identified 115 as potentially relevant. After further assessment we found that 99 references belonging to seven studies were eligible and 16 references were excluded with reasons given. The latest search was run in August 2011.
Included studies
Full details of all included studies can be found in the Characteristics of included studies table.
Study design
All the included studies were multi-centre, randomised, doubleblind, placebo-controlled with a parallel-group design. 
Sample size
The studies included 5997 participants of which 2991 were randomised to LABA treatment and 3006 to ICS treatment. TORCH 2007 was the largest study with 3093 participants. The other studies had between 300 to 800 participants each.
Participants
The mean age of participants was 64 years. 
Permitted co-treatment
All included studies allowed reliever medication, such as terbutaline or salbutamol, when necessary to relieve symptoms. In the majority of studies tiotropium was not a permitted co-treatment. Calverley 2003 also allowed courses of oral corticosteroids (maximum three weeks per course) and antibiotics in the event of exacerbations, and parenteral steroids or nebulised treatment (single injections or inhalations), or both, at emergency visits. Tashkin 2008 allowed oral and parenteral corticosteroids (not depot formulations), acute use of xanthines, increased use of inhaled beta-adrenoceptor agonists and ipratropium bromide, nebulized beta-adrenoceptor agonists and ipratropium bromide. TORCH 2007 allowed patients to continue any medication for COPD other than corticosteroids and inhaled long-acting bronchodilators. TRISTAN 2003 allowed regular treatment with anticholinergics, mucolytics and theophylline. All non-COPD medications could be continued if the dose remained constant, whenever possible, and if their use would not be expected to affect lung function.
Outcomes
All the included studies looked at COPD exacerbations, FEV 1 , health-related quality of life and adverse events. Most of the studies also recorded symptoms, use of reliever medication, dyspnoea and peak expiratory flow (PEF).
Excluded studies
Fourteen references from 11 studies were excluded as they failed to meet the eligibility criteria for the review (see Characteristics 
Risk of bias in included studies
An assessment of the risk of bias for each study is presented in the Characteristics of included studies, and an overview of the findings is shown in Figure 1 . reported using computer-generated randomisation schedules for list generation and were therefore judged to be at low risk of bias. Patients who met the inclusion criteria were assigned the next consecutive treatment number from the generated list. Information regarding sequence generation for the other included studies, and details of allocation concealment procedures for all included studies (except TORCH 2007), were not reported and these were judged to be at unclear risk of bias. In TORCH 2007 the principal investigators were provided with the participant's treatment number as well as a treatment pack number through an automated 24-hour telephone number. For all other studies there were insufficient descriptions of allocation concealment methods to allow judgement of anything other than unclear risk of bias against this criterion. 
Blinding
Incomplete outcome data
All included studies had substantial withdrawal rates (20% to 40%). However, the rates were broadly comparable in the ICS and LABA treatment groups with the exception of Mahler 2002, where there was a notable difference between ICS (40%) and LABA (28%) dropout rates. Most of the studies, including Mahler 2002, described intention-to-treat data analyses, though TRISTAN 2003 did not state whether follow-up data were collected for discontinued patients.
Selective reporting
All included trials adequately reported the outcome data specified in the published methods and were therefore judged to be at low risk of bias for this criterion.
Effects of interventions
Please note that a number of trials reported the difference between ICS and LABA arms but did not report the appropriate variance around this difference. In these cases we calculated the variance of the difference between ICS and LABA using the variances of all the trial arms, see Appendix 1. Variances were not imputed from other studies in any of the analyses in this review.
Inhaled corticosteroid versus long-acting beta 2 -agonist Primary outcome: exacerbations
Four studies (4750 participants) reported exacerbation rate ratios between ICS or LABA and placebo or a ICS/LABA combination (Calverley 2003; Szafranski 2003; TRISTAN 2003; TORCH 2007) . Analysis of the rate ratio (RR) between ICS and LABA was not statistically significant (RR 0.96; 95% confidence interval (CI) 0.89 to 1.02) (Analysis 1.1), and the CI was narrow enough to exclude large differences between the two treatments, see Figure  2 . There was no evidence of a class effect when comparing the fluticasone/salmeterol trials to the budesonide/formoterol trials in a subgroup analysis (Chi 2 = 1.57, df = 1, P = 0.21). There was no statistically significant difference in exacerbation RR between studies of ≤ 1 year and > 1 year of treatment (Chi 2 = 0.11, df = 1, P = 0.75), see 
Primary outcome: hospitalisations due to exacerbations
Exacerbations leading to hospitalisations were only reported in a single trial (TORCH 2007) with 3093 participants. A comparison of rate ratios showed there was no significant difference in the risk of hospitalisation due to exacerbation between fluticasone and salmeterol (RR 1.07; 95% CI 0.91 to 1.26) (Analysis 1.3).
Primary outcome: pneumonia
Three studies (4164 participants) reported the number of patients suffering from episodes of pneumonia as adverse events (Calverley 2003; TORCH 2007; Tashkin 2008) . The three-year study, TORCH 2007 (3093 participants), showed a significantly higher incidence of pneumonia in patients on fluticasone compared to patients on salmeterol (OR 1.43; 95% CI 1.13 to 1.81 Figure 4 . This result is also shown as a Cates plot in Figure 5 , which demonstrates that for every 100 people treated over 2.4 years, there would be seven pneumonia cases if they were all given LABA and nine pneumonia cases if they were all given ICS. These calculations are based on the assumption that, in such a hypothetical situation, the patients were not also receiving the other treatment. Five of the included studies (5086 participants) classified pneumonia as a serious adverse event (Mahler 2002; Hanania 2003; TRISTAN 2003; TORCH 2007; Tashkin 2008) . A separate analysis was conducted for these studies as the distinction between adverse event and serious adverse event classification of pneumonia was unclear. Of these studies, four compared fluticasone versus salmeterol and one compared budesonide versus formoterol. The pooled result was again dominated by TORCH 2007 and showed a significantly greater risk of pneumonia for patients on ICS compared to patients on LABA (Peto OR 1.48; 95% CI 1.13 to 1.93), see Figure 6 . There was no statistically significant difference in pneumonia, classified as a serious adverse event, between studies of ≤ 1 year and > 1 year of treatment (Chi 2 = 0.71, df = 1, P = 0.40), or between the studies using fluticasone/salmeterol and budesonide/formoterol (Chi 2 = 0.42, df = 1, P = 0.51). Secondary outcome: mortality
All the included studies (5997 participants in seven studies) reported the number of deaths from any cause during the treatment period. The three-year TORCH 2007 study was the only one to report mortality status for all randomised participants, including study withdrawals. The number of events was generally low except for TORCH 2007, which reported significantly more deaths among patients treated with fluticasone compared to salmeterol (Peto OR 1.23; 95% CI 1.01 to 1.50). The pooled result showed that there was no statistically significant difference between ICS and LABA on mortality (Peto OR 1.17; 95% CI 0.97 to 1.42; I 2 = 37%), see Analysis 1.9. Since I 2 was greater than 20% we performed sensitivity analysis using the random-effects model (OR 0.98; 95% CI 0.59 to 1.64); this model gives much less weight to TORCH 2007, which explains the reversal of direction of the treatment effect. There was heterogeneity between the two subgroups of fluticasone versus salmeterol and budesonide versus formoterol (I 2 = 73%) but the difference was not statistically significant (Chi 2 = 3.64, df = 1, P = 0.06). -102.76 ). Because of the many substantial differences between the two studies, the results were not pooled.
Peak expiratory flow (PEF)
Tashkin 2008 (559 participants) reported the difference in change in morning PEF between formoterol and budesonide that was not statistically significant (MD -4.26L/min; 95% CI -9.26 to 0.74).
Secondary outcome: quality of life
We could extract data on changes in health-related quality of life from three studies involving 4398 participants that used the St George's Respiratory Questionnaire (SGRQ) (TRISTAN 2003; TORCH 2007; Tashkin 2008) . Patients treated with ICS showed greater improvements in quality of life compared to those treated with LABA (MD -0.74; 95% CI -1.42 to -0.06). This difference was small in relation to the threshold of four units for a clinically significant difference. There was no heterogeneity between the subgroups, see Analysis 1.10. On the TDI scale a higher score represents an improvement in perceived breathlessness, and on the 0 to 4 dyspnoea scale a higher score represents more breathlessness. There was no statistically significant difference (MD 0.03; 95% CI -0.02 to 0.08) between ICS and LABA using the 0 to 4 point dyspnoea scale and although there was heterogeneity between the two subgroups (fluticasone versus salmeterol and budesonide versus formoterol) (I 2 = 57%), this was not statistically significant (Chi 2 = 2.31, df = 1, P = 0.13) see Analysis 1.11. However, there was also moderate heterogeneity among the studies comparing budesonide and formoterol (I 2 = 30%) and among all the included studies (I 2 = 47%). There was no statistically significant difference between fluticasone and salmeterol treatment in studies using the TDI (Mahler 2002; Hanania 2003) in 688 participants (MD 0.26; 95% CI -0.21 to 0.74). CIs for the comparisons were wide using either dyspnoea scale.
Symptoms
Symptom score data could be extracted from three studies including 1470 participants (Calverley 2003; Szafranski 2003; Tashkin 2008) . The mean improvement in symptom score was greater with LABA than ICS (MD 0.21; 95% CI 0.06 to 0.37) although there was no coherent pattern between the studies resulting in considerable heterogeneity (I 2 = 62%). When analysed with a random-effects model there was no statistically significant difference between ICS and LABA treatment (MD 0.22; 95% CI -0.03 to 0.47).
Secondary outcome: rescue medication
Tashkin 2008 (559 participants) reported a statistically significant difference in the use of rescue medication during the treatment period that favoured formoterol (MD 0.56 puffs/24 h; 95% CI 0.10 to 1.02).
Secondary outcome: adverse events
All adverse events
The number of patients suffering adverse events could be extracted from five studies including 5086 participants (Mahler 2002; Hanania 2003; TRISTAN 2003; TORCH 2007; Tashkin 2008) . Patients receiving ICS had more adverse events (2122/ 2552) compared to those receiving LABA (2070/2537), but the difference was not statistically significant (OR 1.12; 95% CI 0.96 to 1.30). There was no heterogeneity between the subgroups.
Serious adverse events (non-fatal)
Data on the number of non-fatal, serious adverse events could be obtained from three of the included studies (Calverley 2003; Szafranski 2003; Tashkin 2008 Tashkin ) (1470 . These three studies all compared the risk of serious adverse events associated with budesonide treatment versus formoterol, which was not statistically significant (OR 1.01; 95% CI 0.77 to 1.31). Data on the number of participants experiencing one or more non-fatal, serious adverse events were obtained from a further three of the included studies (Mahler 2002; Hanania 2003; TRISTAN 2003) (1434 participants). These studies all compared fluticasone versus salmeterol. There was considerable heterogeneity among the studies (I 2 = 54%), and there was no statistically significant difference between the treatments (OR 0.93; 95% CI 0.67 to 1.31). This was consistent when analysed with a random-effects model (OR 1.17; 95% CI 0.60 to 2.28) (Analysis 1.15).
Secondary outcome: all cause hospitalisations
None of the included studies reported the number of patients admitted to hospital for any cause.
Secondary outcome: withdrawals
All seven of the included studies reported the number of participant withdrawals from each treatment arm. Overall there was no statistically significant difference in the number of withdrawals between patients on ICS and LABA (OR 1.02; 95% CI 0.92 to 1.14; I 2 = 29%) (Analysis 1.16). Subgroup analysis showed no statistically significant differences between fluticasone versus salmeterol (OR 1.05; 95% CI 0.92 to 1.18) and budesonide versus formoterol (OR 0.96; 95% CI 0.76 to 1.20). However, there was moderate heterogeneity among the studies comparing fluticasone and salmeterol (I 2 = 58%).
D I S C U S S I O N
Summary of main results
This systematic review set out to investigate the relative effects of inhaled corticosteroids and long-acting beta 2 -agonists on clinical endpoints in patients with stable COPD using direct comparisons from randomised trials. Seven randomised, active-control, doubleblind trials involving 5997 participants were identified. The results of the review were dominated by the largest study, TORCH 2007, for many outcomes (exacerbations, pneumonia, mortality, healthrelated quality of life and withdrawals). The review showed no statistically significant differences between ICS and LABA in the number of patients experiencing exacerbations or the number of exacerbation per patient year (rate ratio). This result was accompanied by narrow confidence intervals, which suggests that there may not be a big difference in exacerbation rates between ICS and LABA. Given the pharmacological differences between the drugs, it seems reasonable to conclude that they are exerting different benefits (albeit of seemingly equal clinical importance) and this endorses the assumption that exacerbations are complex in terms of their pathophysiology. Data on exacerbations leading to hospitalisation were only reported by TORCH 2007 and also showed no statistically significant difference between ICS and LABA. Exacerbation rates are often higher in patients who withdraw from a study before completion (Keene 2008 ) and this could suggest that the rates used in this review underestimate population exacerbation frequencies. However, this would only represent potential analytical bias in the presence of differential dropout rates, and this study has shown parity between ICS and LABA withdrawals. The risk of pneumonia was significantly greater for patients on ICS than patients on LABA, whether classified as an adverse event (OR 1.38; 95% CI 1.10 to 1.73) or a serious adverse event (Peto OR 1.48; 95% CI 1.13 to 1.94). The increased incidence of pneumonia with ICS compared to LABA appears independent of study length. However, it should be noted that event rates were very low (3% or less) in all studies with the exception of TORCH 2007, the largest and longest of all the included studies. Differences in mortality between ICS and LABA were not statistically significant (Peto OR 1.17; 95% CI 0.97 to 1.42). However, TORCH 2007 was the only study to record mortality status for all randomised participants, including withdrawals, and it recorded significantly more deaths on the ICS fluticasone compared to the LABA salmeterol (OR 1.23; 95% CI 1.01 to 1.50). It should be noted that very low event rates in the majority of studies may be due, in part, to follow-up limited to patients remaining in the study, and the study duration. Conversely, interpretation of mortality data is complicated by the tendency for patients who withdraw to then be given the other active study therapies, for example patients withdrawing from the LABA arm are prescribed ICS, though this is likely to reduce differences between groups rather than to enhance them. Treatment with ICS led to a smaller improvement in lung function (pre-bronchodilator FEV 1 ) compared to LABA, although the difference was relatively small (MD -18.99 mL; 95% CI -37.46 to -0.52). Post-dose FEV1 was reported in two studies and gave very different results with high heterogeneity, and there were too many differences between the studies to be able to pool the outcome. The change in health-related quality of life was also significantly different between the treatment arms but with this outcome improvements were greater with ICS treatment than with LABA (SGRQ MD -0.74; 95% CI -1.42 to -0.06). However, the differences in health-related quality of life were small in comparison to the threshold for a clinically important difference (defined as a change of four units). Improvements in quality of life in favour of ICS may support the idea that the drug exerts its benefits not just in terms of alleviating or abrogating lung function impairment (noting that LABA also improves lung function). Given the possibility that COPD is a systemic disease, it may be that drug effects on airways inflammation have wider consequences, that is reductions in systemic consequences of airways inflammation. There were no significant differences for hospitalisations due to exacerbations, mild exacerbations, peak expiratory flow, dyspnoea, symptoms scores, rescue medication, adverse events, all cause hospitalisations, and withdrawals from studies.
Overall completeness and applicability of evidence
• This review has provided evidence to suggest that differences in exacerbation rates between COPD patients treated with ICS and those treated with LABA are unlikely.
• High withdrawal rates compared to low mortality rates introduces considerable uncertainty in the analysis of mortality from the smaller, shorter studies. However, TORCH 2007, which was the only study with complete mortality data, reported higher mortality with ICS therapy compared to LABA therapy.
• The size and length of TORCH 2007 lends substantial weight to evidence for an increased risk of pneumonia with ICS treatment compared to LABA treatment. However, event rates across the remaining studies were low and the results should therefore be interpreted with caution.
• The indirect comparisons between the trials comparing budesonide with formoterol and fluticasone with salmeterol do not allow any conclusions to be drawn about the relative efficacy and safety of budesonide and fluticasone or formoterol and salmeterol.
• Data synthesis was limited by the lack of common data for several outcomes. The definition of change and impact differed substantially with studies using: a) different outcome measures, e.g. pre-bronchodilator or post-bronchodilator FEV1, b) different units of analysis, e.g. mL or % change from baseline, c) no exact measures of variability for differences between treatments, e.g. no CI, no exact P value.
Quality of the evidence
The included studies were generally of good quality, free from selective reporting of results, and all but one of the studies used intention-to-treat data analysis to control for the relatively high withdrawal rates, which are common in long (≥ six-month) COPD trials. However, because of the high number of withdrawals in the included studies, the results for the dichotomous outcomes with relatively few events (such as mortality, pneumonia and serious adverse events) are less reliable when the withdrawals have not been followed up, and must be interpreted with caution.
Potential biases in the review process
Several of the studies did not report on the statistical variance of the difference between the ICS and LABA arms as these were not the primary issues in those studies. We were able to calculate these variances from exact P values or confidence intervals (see Appendix 1). However, for some of the outcomes several studies only provided approximate P values (see Table 1 ) and as we were not able to obtain further information from the authors data for these outcomes could not be used in this review.
Agreements and disagreements with other studies or reviews
Several systematic reviews have tried to clarify the contribution of ICS and LABA to the benefits and risks of the combination inhalers in COPD. Treatment with ICS and LABA combination inhalers has been shown to significantly reduce exacerbation rates in COPD patients compared to placebo (rate ratio 0.74; 95% CI 0.7 to 0.8) (Nannini 2007a). In comparison to placebo, combination therapy also significantly reduced all cause mortality (primarily based on TORCH 2007) (OR 0.79; 95% CI, 0.65 to 0.96); improved health-related quality of life, symptoms and lung function; but increased the risk of pneumonia (OR 1.83; 95% CI 1.51 to 2.21) (Nannini 2007a). Systematic reviews comparing ICS treatment with placebo have shown that ICS reduced the occurrence of exacerbations (risk ratio (RR) 0.82; 95% CI 0.73 to 0.92) (Agarwal 2010), slowed the decline in health-related quality of life (MD -1.22 units/year; 95% CI -1.83 to -0.60) and improved FEV 1 after two to six months of treatment (Yang 2007) . Although long-term use of ICS (longer than six months) did not reduce the rate of decline in FEV 1 (MD 5.80 mL/year with ICS; 95% CI -0.28 to 11.88), it was not associated with a higher mortality rate compared to placebo (OR 0.98; 95% CI 0.83 to 1.16) (Yang 2007) . Neither of these reviews looked at adverse events, including pneumonia. Compared to placebo, LABA treatment has also been shown to reduce exacerbations (RR 0.78; 95% CI 0.67 to 0.91) and improve health-related quality of life (MD -3.26; 95% CI -4.57 to -1.96) without a significant effect on mortality (RR 0.95; 95% CI 0.80 to 1.14) (Appleton 2006; Rodrigo 2008) . The reviews of placebo-controlled studies have shown benefits for both monotherapies without an increased risk of mortality. Comparing the effects of combination inhaler to those of its components has shown that all cause mortality is lower with combined treatment than with ICS alone (OR 0.77; 95% CI 0.63 to 0.94) (Nannini 2007), whereas there was no significant difference in mortality between combined inhalers and LABA alone ( • both ICS and LABA may contribute to a decrease in exacerbation rates but according to the results from this review there is not a large difference between them;
• although ICS therapy benefits COPD patients, it also increases the risk of pneumonia;
• the effect of ICS and LABA on mortality is more complicated. According to Yang 2007 and Rodrigo 2008 there is not enough evidence to say that ICS or LABA influences all cause mortality on its own. However, in combination they seem to cause a reduction in mortality both compared to placebo (Nannini 2007a) and to ICS alone (Nannini 2007) but not compared to LABA (Nannini 2007b; Rodrigo 2009 ). This review supports the view that there is insufficient evidence for the impact of LABA and ICS on mortality and the differential impact of ICS and LABA on mortality remains unclear. Our review showed no overall difference in mortality rates between the monotherapies but the study with the most reliable mortality data (TORCH 2007) showed lower rates for patients receiving LABA therapy;
• according to this review LABA therapy is associated with small improvements in FEV 1 compared to ICS, which is consistent with the results from the above reviews; and
• both ICS and LABA increase the patient's quality of life but ICS therapy is associated with slightly larger improvements.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The benefits of ICS therapy for COPD patients may be similar to those of LABA, but there is potentially an increased incidence of pneumonia. These data support both national and international guidelines stating that the choice of drugs should take into account the person's symptomatic response, the drug's potential to reduce exacerbations and side effects (GOLD 2010; NICE 2010) .
Implications for research
Additional work is required in assessing the risks and benefits of budesonide/formoterol combination inhalers. Potential class effects between fluticasone and budesonide are still unknown as are the influence of high and low doses on benefits and risks for both drugs. The lack of key standardised outcomes is an impediment to the synthesis of trial data for systematic reviews. We strongly recommend international consensus on the identification and definition of key common outcomes, for example change from baseline in pre-bronchodilator FEV 1 (mL), change from baseline in health-related quality of life, and complete mortality data for all randomised participants including study withdrawals.
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R E F E R E N C E S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Calverley 2003
Methods Design: a multi-centre, randomised, double-blind, parallel-group, placebo-controlled study. Trial duration was 2 week run-in period followed by 52 weeks treatment. The trial included 109 centres in 15 countries Participants Participants: 512 patients were randomised (budesonide 257; formoterol 255) Baseline characteristics: mean age 64 years; 74% male; mean FEV 1 1.0 L; mean FEV 1 predicted 36%; mean SGRQ 48 Inclusion criteria: GOLD defined COPD (stages III and IV); ≥ 40 years; COPD symptoms > 2 years; smoking history ≥ 10 pack years; FEV 1 /FVC ≤ 70% pre-bronchodilator; FEV 1 ≤ 50% predicted; use of short acting beta 2 -agonists as reliever medication; ≥ 1 COPD exacerbation requiring oral corticosteroids/antibiotics 2 to 12 months before first clinic visit Exclusion criteria: history of asthma/rhinitis before 40 years of age; any relevant cardiovascular disorders; exacerbation of COPD requiring medical intervention within 4 weeks of run-in/during run-in phase; non-allowed medications: oxygen therapy; ICS (aside from study medication), disodium cromoglycate, leukotriene-antagonists, 5-lipoxygenase inhibitors, bronchodilators (other than study medication and terbutaline 0.5 mg as needed), antihistamines, medication containing ephedrine, β-blocking agents Interventions Run-in: all participants received 30 mg oral prednisolone twice daily and 2 x 4.5 mg formoterol twice daily (2 weeks) 1. budesonide 800 µg per day: 2 x 200 µg twice daily 2. formoterol 18 µg per day: 2 x 4.5 µg twice daily Inhaler device: Turbuhaler Co-treatment: terbutaline 0.5 mg as needed, courses of oral corticosteroids (maximum 3 weeks per course) and antibiotics in the event of exacerbations, parenteral steroids and/ or nebulised treatment (single injections/inhalations) at emergency visits The following medications were disallowed from recruitment: inhaled steroids (except the study medication), disodium cromoglycate, leukotriene antagonists or 5-lipoxygenase (5-LO) inhibitors, bronchodilators (other than study medication and terbutaline 0.5 mg as needed), antihistamines, any medication containing ephedrine, and β-blockers, including eye-drops The following medications were withheld prior to recruitment: short-acting inhaled or oral β 2 -agonists (6 h before), inhaled or oral long-acting β 2 -agonists (48 h), inhaled short-acting anticholinergics (8 h), inhaled long-acting anticholinergics (7 days), xanthine-containing derivatives (48 h), xanthine-containing derivatives (24 h 
Tashkin 2008
Methods Design: a multi-centre, randomised, double-blind, double-dummy, placebo-controlled, parallel-group study. Trial duration was 2 week run-in, 6 months treatment, and telephone follow-up 4 weeks after the last study visit. The trial included 194 centres in 5 countries (42% US) Participants Participants: 559 patients were randomised (budesonide 275; formoterol 284) Baseline characteristics: mean age 63 years; 67% male; mean predose FEV 1 1.03 L; mean predose FEV 1 predicted 40% Inclusion criteria: Current or ex-smokers aged ≥ 40 years; clinical diagnosis of COPD with symptoms for > 2 years; ≥ 1 COPD exacerbation requiring oral corticosteroids/ antibiotics 1 to 12 months before first clinic visit; use of SABAs as reliever medication; predose FEV 1 ≤ 50% predicted; predose FEV 1 /FVC ≤ 70%; smoking history ≥ 10 pack years; dyspnoea scale (MMRC) ≥ 2; breathlessness, cough and sputum scale (BCSS) score ≥ 2 per day for at least half of the 2-week run-in period Exclusion criteria: history of asthma/rhinitis before 40 years of age; significant/unstable cardiovascular disorder; clinically significant respiratory tract disorder other than COPD; homozygous α-1 antitrypsin deficiency; if the patient needed additions or alterations to their usual COPD maintenance therapy or an increment in rescue therapy due to worsening symptoms within 30 days before screening or during the run-in; oral or ophthalmic non-cardioselective beta-adrenoceptor antagonists, oral corticosteroids, pregnancy and breast-feeding Interventions Run-in: 2 weeks. Patients continued ICS mono-therapy if they had previously been receiving ICS alone or in combination with a LABA, and patients who had previously been receiving anticholinergic therapies were placed on stable doses of ipratropium bromide. A short-acting beta 2 -adrenoceptor agonist was allowed for rescue use 1. budesonide 640 µg per day: 2 x 160 µg twice daily (Turbuhaler) 2. formoterol 18 µg per day: 2 x 4.5 µg twice daily (pMDI) Co-treatment: Allowed: Ephedrine-free (or other bronchodilator-free) antitussives and mucolytics, nasal corticosteroids, stable-dose non-nebulized ipratropium bromide, oral or ophthalmic cardioselective beta-adrenoceptor antagonists, study-provided salbutamol (albuterol) as rescue medication, medications allowed for exacerbations after randomisation: oral and parenteral corticosteroids (not depot formulations), acute use of xanthines, increased use of inhaled beta-adrenoceptor agonists and ipratropium bromide, and nebulized betaadrenoceptor agonists and ipratropium bromide Low risk The withdrawal rates were 23% in the inhaled corticosteroid (budesonide) group and 22% in the long-acting beta 2 -agonist (formoterol) group. However the efficacy analysis set (i.e. intention-to-treat population) included all randomised patients who received at least one dose of study medication and contributed sufficient data for at least one co-primary or secondary efficacy endpoint during the randomised treatment period Selective reporting (reporting bias) Low risk All collected data reported TORCH 2007 (Continued) logical order.
• Each subject who satisfied the randomisation criteria was assigned a unique treatment number from the Interactive Voice Response (IVR) system which is part of the System for Central Allocation of Drug (SCAD). Once a treatment number had been assigned to a subject, it could not be assigned to any other subject. Neither the subject nor the investigator knew to which treatment arm a subject had been allocated.
• At each treatment visit the subject was provided with a treatment pack. Every pack number was unique and corresponded to the study medication pack which was dispensed to the subject at the visit A specialist IVR system company, ClinPhone, managed this system. At the randomisation visit (Visit 2) the principal investigator or designee contacted the IVR system through an automated 24-hour telephone number; upon providing their unique personal identification number (PIN) and answering a series of questions, the site was provided with the subject's treatment number as well as a pack number Blinding (performance bias and detection bias) All outcomes
Low risk
Neither the subject nor the investigator knew to which treatment arm a subject had been allocated. At each treatment visit each subject was issued with a treatment pack containing DISKUS/ACCUHALER inhalers. The inhalers contained either of the four treatments (salmeterol/fluticasone propionate combination product, fluticasone propionate, salmeterol, or placebo) in accordance with the randomisation schedule. The inhalers were labelled in accordance with all applicable regulatory requirements. Each treatment pack and study treatment inhaler was labelled with the protocol number, storage and dosing instructions by GW Research and Development
Incomplete outcome data (attrition bias) All outcomes
Low risk For patients who withdrew from the study prematurely, all data on exacerbations, health status, and lung function available at the time of a patient's withdrawal from
